Volunteer Intake Remains Open as the Company Prepares to Post Updated Evaluation Results on Its Corporate Website in ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Melanoma detection is rising, but mortality isn't. Are we catching more dangerous cancers or overlabeling harmless lesions?

In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes. Ojemda (tovorafenib) shrank tumors in 10 of 23 adults ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

Neoadjuvant Immunotherapy Is Here to Stay / cancer care, Cancer research, immunotherapy, James Larkin, Leslie Fecher, ...

It's not a cure for baldness. But it might eliminate crow's feet and laugh lines by telling the tissues in your face how to ...

Moderna Inc MRNA shares are rising Friday to a fresh 52-week high. The stock enters the Nasdaq-100 Index. Here’s what you should know. Moderna stock is at critical resistance. Why is MRNA stock ...

Doctors in Illinois and Michigan detailed a 46-year-old man with a previous history of skin cancer who bought the peptide Melanotan-II to help with his tanning. Five weeks after he started using the ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

Pills that rival biologics, weight-loss drugs paired with psoriasis treatment and a phase 3 win for a personalized mRNA ...

A three-drug combination helped treatment-resistant melanoma respond again to immune-based therapy in mouse experiments. The ...